VOICE-Early Response to Vedolizumab and Ustekinumab in Participants With Crohn's Disease: A Prospective Observational Study - Trial NCT06249555
Access comprehensive clinical trial information for NCT06249555 through Pure Global AI's free database. This phase not specified trial is sponsored by Alimentiv Inc. and is currently Not yet recruiting. The study focuses on Crohn's Disease. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Alimentiv Inc.
Timeline & Enrollment
N/A
Mar 31, 2024
Sep 30, 2026
Primary Outcome
To assess time of onset of biologic therapy in pain interference
Summary
The primary aim of this study is to explore the time course of response to Vedolizumab in
 participants with CD as measured by the Patient-Reported Outcomes Measurement Information
 System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs
 (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to
 participate in social roles and activities); other PRO measures will also be assessed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06249555
Non-Device Trial